Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality.

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-12-24 DOI:10.1007/s12325-024-03070-x

Kazuna Tsubouchi, Hisatomi Arima, Taiki Emoto, Hiroshi Nakazawa, Takahiro Kitano, Masashi Mikami, Chikao Aoyagi, Hiroshi Matsuzaki, Kosuke Tominaga, Naotaka Gunge, Takeshi Miyazaki, Yu Okabe, Nobuyuki Nakamura, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuhiro Haga

{"title":"Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality.","authors":"Kazuna Tsubouchi, Hisatomi Arima, Taiki Emoto, Hiroshi Nakazawa, Takahiro Kitano, Masashi Mikami, Chikao Aoyagi, Hiroshi Matsuzaki, Kosuke Tominaga, Naotaka Gunge, Takeshi Miyazaki, Yu Okabe, Nobuyuki Nakamura, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuhiro Haga","doi":"10.1007/s12325-024-03070-x","DOIUrl":null,"url":null,"abstract":"Introduction: The present study aimed to investigate the prescribing patterns of anticholinergics (anti-AChR) or β3-adrenergic agonists (β3A) in the pharmacotherapy of overactive bladder (OAB) and to evaluate the differences in the frequency of adverse events (AEs) between the two types of drugs using a large-scale medical claims database.Methods: This cohort study was conducted using the JMDC claims database between May 2015 and April 2023. Patient characteristics, prescription and treatment patterns of anti-AChR and β3A, and the incidence of AEs have been described.Results: Overall, 70,936 patients were analyzed [mean age, 53.6 (standard deviation: 12.3) years]. Among women (48.5%; 34,439), 21.4% initially received anti-AChR and 27.2% received β3A; among men (51.5%; 36,497), 17.1% initially received anti-AChR and 34.3% received β3A. Most patients (79.6%; women, 83.5%; men, 75.8%) visited clinics. About 10% of patients had a treatment change: 5.6% switched the drug type (change from anti-AChR to β3A or vice versa), and 4.0% had an add-on of another drug type. The incidence rate of treatment change per 100 patient-years was higher with β3A in both women (12.39) and men (13.65). In the multivariable analysis, initial prescription with anti-AChR compared with β3A did not show any association with the risk of AEs.Conclusion: This large-scale database study revealed that treatment for OAB is often initiated with β3A and prescribed mainly at clinics. Changes or additions to initial prescriptions were as low as about 5%, indicating that raising awareness among physicians treating OAB is particularly important to improve the quality of life of patients with OAB. Our study also showed that the incidence of AEs was not associated with the initially prescribed drug type. Continued exploration is warranted to further clarify the risk of AEs with each prescription.","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-024-03070-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The present study aimed to investigate the prescribing patterns of anticholinergics (anti-AChR) or β3-adrenergic agonists (β₃A) in the pharmacotherapy of overactive bladder (OAB) and to evaluate the differences in the frequency of adverse events (AEs) between the two types of drugs using a large-scale medical claims database.

Methods: This cohort study was conducted using the JMDC claims database between May 2015 and April 2023. Patient characteristics, prescription and treatment patterns of anti-AChR and β₃A, and the incidence of AEs have been described.

Results: Overall, 70,936 patients were analyzed [mean age, 53.6 (standard deviation: 12.3) years]. Among women (48.5%; 34,439), 21.4% initially received anti-AChR and 27.2% received β₃A; among men (51.5%; 36,497), 17.1% initially received anti-AChR and 34.3% received β₃A. Most patients (79.6%; women, 83.5%; men, 75.8%) visited clinics. About 10% of patients had a treatment change: 5.6% switched the drug type (change from anti-AChR to β₃A or vice versa), and 4.0% had an add-on of another drug type. The incidence rate of treatment change per 100 patient-years was higher with β₃A in both women (12.39) and men (13.65). In the multivariable analysis, initial prescription with anti-AChR compared with β₃A did not show any association with the risk of AEs.

Conclusion: This large-scale database study revealed that treatment for OAB is often initiated with β₃A and prescribed mainly at clinics. Changes or additions to initial prescriptions were as low as about 5%, indicating that raising awareness among physicians treating OAB is particularly important to improve the quality of life of patients with OAB. Our study also showed that the incidence of AEs was not associated with the initially prescribed drug type. Continued exploration is warranted to further clarify the risk of AEs with each prescription.

查看原文本刊更多论文

OAB的临床特点及药物治疗现状：理想与现实。

前言：本研究旨在探讨抗胆碱能药物（anti-AChR）或β3-肾上腺素能激动剂（β3A）在药物治疗膀胱过动症（OAB）中的处方模式，并利用大型医疗索赔数据库评估两种药物不良事件（ae）频率的差异。方法：本队列研究于2015年5月至2023年4月期间使用JMDC索赔数据库进行。本文描述了抗achr和β3A的患者特征、处方和治疗模式以及ae的发生率。结果：总共分析了70,936例患者[平均年龄53.6岁（标准差：12.3）岁]。女性占48.5%；34,439)， 21.4%最初接受抗achr治疗，27.2%接受β3A治疗；男性占51.5%；36,497)， 17.1%最初接受抗achr治疗，34.3%接受β3A治疗。多数患者(79.6%；女性,83.5%;男性（75.8%）去过诊所。大约10%的患者改变了治疗方法：5.6%的患者改变了药物类型（从抗achr改为β3A或反之亦然），4.0%的患者增加了另一种药物类型。女性（12.39）和男性（13.65）的β3A治疗改变发生率均高于男性（12.39）。在多变量分析中，与β3A相比，初始处方抗achr与ae的风险没有任何关联。结论：这项大规模的数据库研究表明，OAB的治疗通常以β3A开始，主要在诊所开处方。改变或增加初始处方的比例低至约5%，表明提高治疗OAB的医生的认识对改善OAB患者的生活质量尤为重要。我们的研究还表明，不良反应的发生率与最初处方的药物类型无关。需要继续研究以进一步明确每种处方的不良反应风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.